44 2033180199
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Nanotechnology Letters

Sign up for email alert when new content gets added: Sign up

Bone marrow, peripheral blood and plasma for quantitation of BCR-ABL transcript in Chronic Myeloid Leukemia

Webinar on Nanomedicine: Nanotechnology and Pharmaceutics

March 07, 2022

The Ha Vy

Cho Ray hospital, Vietnam

Posters & Accepted Abstracts: Nanotechnology Letters

Abstract :

Molecular diagnosis based on the quantitative monitoring of BCR-ABL transcript in Chronic Myeloid Leukemia (CML) using quantitative real-time PCR (qRT-PCR) has been performed in the bone marrow. Recently, the reliability of using the source of peripheral as well as plasma for BCR- ABL transcript quantitation has been questioned. We herein reported a study on 172 paired samples, partitioned into 3 groups, including before treatment (newly diagnosed CML), under 1 year, and more than 1 year after initiation of TKI therapy for BCR-ABL transcript quantitation as performed by qRT-PCR. Based on the results, quantitatively, we concluded that there was only agreement of BCR-ABL measurements among bone marrow, peripheral blood, and plasma in the group of the newly diagnosed CML patients based on the evaluation of %IS-NCN and the kappa-value. Our data suggested that the source sample of peripheral blood and plasma were suitable for the BCR-ABL transcripts quantitation for CML patients without undergoing TKI treatment. The plasma-based quantification assay was more sensitive in untreated patients compared to the bone marrow test.

 
Google Scholar citation report
Citations :

Nanotechnology Letters received citations as per Google Scholar report

Nanotechnology Letters peer review process verified at publons
pulsus-health-tech
Top